摘要:
A Universal Serial Bus (USB) head interface device and an apparatus with the USB head interface device are provided. The USB head interface device includes a USB head component (10) and a tension rod base (20). The tension rod base includes: a first locating groove (21) provided on an inner wall of the tension rod base; an elastic fastening member (30) provided on the inner wall of the tension rod base; a tension rod (40) provided in the tension rod base in a stretchable manner, the tension rod includes a first locating rib (41) provided on an outer wall of the tension rod, and the first locating rib is provided with a structure adaptive to the first locating groove; and a rotating shaft (60) which passes through two first through-holes on a second end of the tension rod to connect the tension rod and the USB head component. Wherein, the elastic fastening member is provided with a structure locking a gear (50). A connecting structure between a USB head and a USB body of the USB interface apparatus is simple and is easy to use.
摘要:
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.
摘要:
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
摘要:
Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.
摘要:
The present invention is related to antibodies directed to the antigen PDGFD and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen PDGFD. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要:
A system and method providing search results based on linguistic analysis is provided. The method comprises receiving content from one or more documents associated with search parameters entered by a user. Language associated with the content based on linguistic parameters is then analyzed. A score is assigned to the content based on the analysis of the language. The content is then ordered by relevance to the user based on the assigned score.
摘要:
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
摘要:
The invention described herein relates to antibodies directed to the antigen phospholipase A2 (PLA2) and uses of such antibodies. In particular, in accordance with some embodiments of the invention, there are provided fully human monoclonal antibodies directed to the antigen PLA2. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要:
An anti-human RANKL antibody, a humanized antibody for the anti-human RANKL antibody, a pharmaceutical composition and a use thereof are provided. The anti-human RANKL antibody is capable of bonding specifically with an amino acid sequence of SEQ ID NO.1, a heavy chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.2-9, and a light chain of the anti-human RANKL antibody includes a variable region in one of amino acid sequences of SEQ ID NO.10-17. The humanized antibody is capable of bonding specifically with human RANKL, a variable region in a heavy chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.6, NO.23, NO.25, NO.27 or NO.29, and a variable region in a light chain of the humanized antibody is selected from amino acid sequences of SEQ ID NO.14, NO.31, NO.33, NO.35, NO.37 or NO.39.
摘要:
The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.